Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Bhushan Akshikar | MD & Executive Director | 66.89M | -- | -- |
| Mr. Juby Chandy | Whole-Time Director & CFO | 68.92M | -- | 1977 |
| Mr. Chinmay Sharma | Executive Vice President of Human Resources | -- | -- | -- |
| Ms. Aparajita Rajput | Vice President of Technology | -- | -- | -- |
| Mr. Ajay Avinash Nadkarni | VP of Administration & Real Estate and Company Secretary | -- | -- | -- |
| Mr. Amit G. Pandey | Executive Vice President of Legal | -- | -- | -- |
| Ms. Simrat Sohal | Vice President of Ethics & Compliance | -- | -- | -- |
| Mr. Ransom D'Souza | Executive Vice President of Communications & Government Affairs | -- | -- | -- |
| Ms. Sukanya Choudhary | Executive Vice-President of Regulatory Affairs | -- | -- | -- |
| Mr. Shourov Mukherjee | Executive Vice-President of Adult Vaccines | -- | -- | -- |
GlaxoSmithKline Pharmaceuticals Limited
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 3,211
Description
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.
Corporate Governance
Upcoming Events
November 7, 2024 at 10:59 AM UTC - November 11, 2024 at 12:00 PM UTC
GlaxoSmithKline Pharmaceuticals Limited Earnings Date
Recent Events
May 31, 2024 at 12:00 AM UTC
Ex-Dividend Date